Sign in Subscribe
Diseases

Breakthrough in Rare Genetic Disease: Longevity Gene Shows Promising Results

Strategic Insights

— 1 min read

Researchers at the University of Bristol and IRCCS MultiMedica have made a groundbreaking discovery using a "longevity gene" found in people who live exceptionally long lives, over 100 years old. This gene has been shown to help keep the heart and blood vessels healthy during aging, and has the potential to reverse the damage caused by Hutchinson-Gilford Progeria Syndrome (HGPS), a rare genetic condition that causes children to age rapidly.

Key Takeaways:

  • Researchers identified a "longevity gene" called LAV-BPIFB4 found in centenarians, which helps keep the heart and blood vessels healthy during aging.
  • The gene was shown to improve heart function, reduce heart tissue damage, and boost the growth of new small blood vessels in animal models genetically engineered to have Progeria.
  • In human cells from Progeria patients, the gene reduced signs of aging and fibrosis without changing progerin levels directly, suggesting it helps protect cells from the effects of progerin.
  • This approach could lead to new treatments for Progeria and age-related heart disease.
  • Dr. Yan Qiu and Professor Paolo Madeddu's team from the Bristol Heart Institute identified the potential of the LAV-BPIFB4 gene in counteracting cardiovascular damage caused by progeria.
  • Professor Annibale Puca's team at IRCCS MultiMedica in Italy collaborated to explore the gene's potential in various pathological conditions.
  • The study paves the way for new treatment strategies for Progeria and suggests a potential new biologic drug.

Statistics:

  • 28 was the age at which Sammy Basso, the oldest known person with Progeria, passed away.
  • Progerin damages cells by disrupting the structure of their nucleus, leading to early signs of aging, especially in the heart and blood vessels.
  • 10 years is the average lifespan for children with Progeria.
  • 100% is the increase in diastolic function improvement in animal models with Progeria after receiving the longevity gene injection.
  • 50% is the reduction in heart tissue damage and the number of 'aged' cells in the heart after receiving the longevity gene injection.

Sources:

  • Signal Transduction and Targeted Therapy
  • University of Bristol
  • IRCCS MultiMedica
  • NewsRx LLC

Please note that the statistics provided are those found in the original text and may not include additional information or context not mentioned.

Read more